CardioProtectMI
Financiado
A new cardioprotective drug for acute treatment of myocardial infarction
Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI). Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals gl...
Ischemic Heart Disease kills more than 1.7M people/year in the EU, the vast majority via a heart attack (Myocardial Infarction - MI). Heart failure (HF) is the major cause of death after MI with a prevalence of >26M individuals globally. While current treatment involving restoration of blood flow to the heart saves the MI patient´s life it also causes additional damage to the heart through an inflammatory reaction (reperfusion injury).
ResoTher’s leading drug candidate, RTP-026, is an immunomodulating therapeutic aimed at resolving inflammation triggered during MI, thereby reducing damage to the heart and significantly decreasing risk of HF and death. Pre-clinical data suggests RTP-026 could reduce post-MI HF by >20%. A Phase I study has been conducted to determine safety and tolerability of RTP-026 in Healthy Volunteers. With the EIC we aim to validate RTP-026 clinical effectiveness by means of a Phase IIa patient proof of principle study and Phase IIb proof of concept study.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2024-02-27
Fecha Fin: 2026-01-31
Fecha Fin: 2026-01-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-27
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
RESOTHER PHARMA AS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5